PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.

ABSTRACT: The relationship between severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) viral load reduction and disease symptom resolution remains largely undefined for coronavirus disease 2019 (COVID-19). While the vaccine-derived immunity takes time to develop, neutralizing monoclonal antibodies offer immediate, passive immunity to patients with COVID-19. Bamlanivimab and etesevimab are two potent neutralizing monoclonal antibodies directed to the receptor binding domain of the spike protein of SARS-CoV-2. This study aims to describe the relationship between viral load and resolution of eight common COVID-19-related symptoms in patients following treatment with neutralizing monoclonal antibodies (bamlanivimab alone or bamlanivimab and etesevimab together), in a phase II clinical trial. Co

SUBMITTER: Ernest CS 

PROVIDER: S-EPMC9111027 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature